Daaweynta Ataxia: Waxa shaqeeya, waxa cusub, iyo waxa xiga

---

Shirweynihii Pan American Parkinson’s Disease and Movement Disorders Congress ee ka dhacay Houston, Texas, USA, waxaa ka mid ahaa kalfadhi guud oo loogu talagalay daaweynta ataxia. Kalfadhigan waxaa asal ahaan hindisay Mario Cornejo-Olivas (Peru) waxaana daadihinayay Orlando Barsottini (Brazil) iyo Malco Rossi (Argentina). Waxay bixisay dulmar guud iyo cusbooneysiin ku saabsan daaweynta hadda la isticmaalo, daawaynta cusub, iyo daawaynta mustaqbalka, oo ay ku jiraan daaweynta hidda-wadaha.

Maxaa ka shaqeeya ataxia? Hagaajinta daryeelka maanta

Muxaadarada "Maxaa ka shaqeeya ataxia? Hagaajinta daryeelka maanta," José Luiz Pedroso (Brazil) wuxuu bixiyay dulmar guud oo ku saabsan xaaladda hadda ee daaweynta ataxia, isagoo sahaminaya daaweyn la xaqiijiyay iyo khibrad shaqsiyeed. Ataxias waxay ka mid tahay xanuunnada ugu niyad jabka badan ee neerfaha. Boqollaal tijaabo ah, laakiin horumarro aad u yar ayaa lagu arkay bukaanada qaba ataxia-da sii xumaanaya.

Marka tan la tixgeliyo, saddex qodob oo muhiim ah ayaa lagama maarmaan ah marka la eego daaweynta ataxias:

Waa maxay daawaynta ku salaysan caddaynta; Faa'iidada calaamadaha iyo, wax ka beddelka cudurka; Waa maxay yoolalka daaweynta ee dhabta ah.

Soo bandhigidan, saddex heer oo daaweyn ah ayaa lagu soo jeediyay: daaweynta calaamadaha (hagaajinta socodka, hadalka, gariirka, dheelitirka; ma beddesho koorsada cudurka); daaweynta wax ka beddesha cudurka (waxay gaabisaa horumarka; waxay ilaalisaa shabakadda maskaxda); iyo daaweynta gaarka ah ee etiology-ga (oo kaliya suurtagal ah tiro yar oo ataxia ah).

Daaweynta gaarka ah ee Etiology iyo ataxias-ka la daweyn karo waxaa ka mid ah: abetalipoproteinemia (kaabis fiitamiin E iyo A); ataxia oo leh yaraanta fitamiin E: kaabis fiitamiin E; cerebrotendinous xanthomatosis (CTX): chenodeoxycholic acid (CDCA); yaraanta CoQ10: kaabis CoQ10; yaraanta GLUT1: cuntada ketogenic; Cudurka Refsum: cunto ay ku yar tahay aashitada phytanic iyo kaloori badan; NPC: miglustat; Episodic ataxia: acetazolamide; ataxias-ka labaad: yaraanta fitamiin / ataxia-ga iswada (Tusaale ahaan Anti-GAD).

Calaamadaha aan ahayn kuwa maskaxda ku jira ayaa ku badan bukaanada qaba ataxias-ka sii xumaanaya. Sidaa darteed, daaweynta guud ee calaamadaha waxaa ka mid noqon kara: amantadine oo loogu talagalay daalka (SCA3 iyo SCAs kale); baclofen / tizanidine / botulinum toxin oo loogu talagalay spasticity: spastic ataxias (SCAs / SPG / ARSACS); levodopa oo loogu talagalay parkinsonism (SCA3 / SCAs / RFC1 / MAS-C); trihexyphenidyl oo loogu talagalay dystonia (SCA3 / SCAs kale); clonazepam iyo melatonin oo loogu talagalay RBD (SCA3 / MAS-C); ciclobenzaprin, carbamazepin iyo gabapentin oo loogu talagalay casiraad iyo xanuun (SCA3).

Dhaqancelinta waxaa lagu muujiyay daaweyn khuseysa, waxaana jira caddayno qaar oo badanaa waxtar u leh hagaajinta calaamadaha bukaanada qaba ataxia cerebellar. Tababar gaar ah ayaa qasab ku ah bukaanada qaba ataxia cerebellar, waana inay diiradda saaraan socodka, aragtida shaqsiyeed, dheelitirka, isku-dubaridka, xakamaynta booska, xasilloonida jirridda, xoogga iyo iska caabbinta, tababarka shaqada ee gaarka ah, iyo daaweynta hadalka. Iyadoo ay jiraan natiijooyin wanaagsan, ma jiraan caddayn cad oo muujinaysa in dib-u-habayntu ay beddeli karto taariikhda dabiiciga ah ee habka neerfaha.

Daawayn kale sida kicinta maskaxda ee aan duullaanka ahayn ayaa sidoo kale laga wada hadlay, sida resonance magnetic transcranial (TMS). Qodobbada wanaagsan waxaa ka mid ah: sabab xooggan oo neerfaha ah, badbaadada, aan duullaanka ahayn, isku-xidhnaan suurtagal ah oo lala yeesho dhaqan-celinta, calaamadaha hore ee faa'iidada calaamadaha; iyo khasaarooyinka waxaa ka mid ah caddayn tayo hoose leh, kala duwanaansho, iswaafaqla'aan hab-maamuuska/natiijada, adkeysiga aan la hubin iyo waxtarka kharashka. Gunaanadkii, caddayn liidata ayaa muujisay natiijooyin wax ku ool ah oo ku saabsan TMS ee ataxia-da cerebellar.

Maxaa cusub oo ku jira daawaynta ataxia?

Muxaadarada "Maxaa cusub ee daaweynta ataxia," Sergio Rodriguez-Quiroga (Argentina) wuxuu ku sharraxay in taariikh ahaan, daaweynta dawooyinka ee ataxia-da dhaxalka ah ay inta badan ku koobnayd hababka calaamadaha. Si kastaba ha ahaatee, maanta, waxaan galaynaa xilli aad u adag oo rajo wanaagsan leh, maadaama horumarradii ugu dambeeyay ay soo jeedinayaan isbeddel macno leh oo ku yimid muuqaalka daaweynta (Ariello, 2025). Tusaalooyinka soo socda ayaa muujinaya kala-guurkan.

Troriluzole, oo bartilmaameedsanaysa sunta glutamate-ka ee dhexdhexaadka ah, ayaa lagu qiimeeyay noocyo badan oo SCA ah daraasad heer dambe ah (NCT03701399) oo aan buuxin ujeeddadeeda ugu weyn; falanqaynta sahaminta ayaa soo jeedisay faa'iido suurtagal ah oo ku jirta SCA3, isbarbardhigga kooxaha taariikhda dabiiciga ah ee la midka ah ayaa muujiyay horumar gaabis ah. Daraasado mustaqbalka ah ayaa loo baahan yahay si loo qeexo doorkeeda caafimaad.

Friedreich's ataxia (FA, ATX-FXN) waxay bixisaa tusaale kale oo ah horumarka muhiimka ah ee la gaaray tobankii sano ee la soo dhaafay ee cilmi-baarista ataxia. Horumarro waaweyn ayaa la gaaray si loo caddeeyo cudurrada faafa, aqoonsashada bartilmaameedyada daaweynta, iyo sifeynta taariikhda dabiiciga ah ee xanuunka. Vatiquinone, oo bartilmaameedsanaya waddooyinka walbahaarka oksaydhka, ayaa lagu qiimeeyay daraasadda MOVE-FA (NCT04577352). Si kastaba ha ahaatee, tijaabada muhiimka ah ma aysan gaarin heerkeedii ugu dambeeyay ee waxtarka. Iyadoo dhiirigelin laga helayo dhinaca farsamada, daraasado dheeraad ah ayaa loo baahan doonaa si si fiican loogu qeexo faa'iidadiisa caafimaad. Iyada oo lagu saleynayo horumarkan sayniska, omaveloxolone wuxuu soo baxay isagoo ah daaweynta ugu horreysa ee cudur-gaar ah oo loogu talagalay FA, ​​taasoo calaamad u ah tallaabo muhiim ah oo hore loogu qaaday goobta (Indelicato, 2025). Iyada oo ku saleysan natiijooyinka tijaabada MOXIe (Lynch, 2021) iyo kordhinta calaamadda furan ee xigta iyo falanqaynta muddada dheer (Lynch, 2024), omaveloxolone waxay muujisay horumar ku yimid shaqada neerfaha marka la barbar dhigo placebo 48 toddobaad, sida lagu cabbiray mFARS, iyadoo xogta muddada dheer ay soo jeedinayso faa'iido joogto ah iyo horumarka cudurka oo gaabis ah. Khibradda dhabta ah ayaa si tartiib tartiib ah u qaabeyneysa sida aan u fasirno saameynteeda caafimaad iyo inaan ku darno dhaqanka caadiga ah. Si kastaba ha ahaatee, safarka daaweynta ee FA aad ayuu uga fog yahay dhammaystirka. Daraasadda BRAVE ee socota ee bukaanada carruurta (NCT06953583) waxay calaamad u tahay tallaabo muhiim ah oo loo qaaday fidinta daaweynta dadka da'da yar iyo fahamka natiijooyinka muddada dheer. Muhiimadda, helitaanka iyo hirgelinta si weyn ayay ugu kala duwan yihiin gobollada oo dhan. Latin Ameerika, waayo-aragnimada omaveloxolone waxay bilaabanaysaa oo keliya, maadaama oggolaanshaha la siiyay tiro kooban oo dalal ah. Barashada gobollada leh khibrad caafimaad oo ballaaran ayaa lagama maarmaan u noqon doonta in lagu wanaajiyo is-dhexgalka daryeelka caadiga ah.

Daaweynta Ataxia si cad ayay isu beddelaysaa. Horumarka laga wada hadlay wuxuu ka tarjumayaa goob ku jirta kala-guur, halkaas oo istaraatiijiyadaha ku salaysan farsamada iyo tijaabooyinka marxaladda dambe ay bilaabayaan inay dib u qaabeeyaan dhaqanka kiliinikada. In kasta oo ay jiraan caqabado muhiim ah, haddana goobtu si cad ayay u socotaa.

Maxaa xiga ee daawaynta ataxia?

Muxaadarada "Maxaa xiga ee daaweynta ataxia," Christopher Stephen (USA) wuxuu aqoonsaday inaan hadda ku jirno xilligii daaweynta hiddaha ee xanuunnada dhaqdhaqaaqa hiddaha (Vázquez-Mojena, 2021; Sartorelli, 2025). Kani waa waqti aad u xiiso badan, gaar ahaan xaaladaha kale ee neerfaha, sida atrophy muruqa laf-dhabarta, waxaa jiray guulo la taaban karo. Si kastaba ha ahaatee, daaweynta hiddaha ee ataxias-ka ayaa aad u adag. Sababta loo isticmaalo tiknoolajiyadan ataxias-ka hiddaha waxaa ka mid ah wax ka qabashada sababta asalka ah ee xanuunnadan iyo guusha kahor kiliinikada, iyadoo la adeegsanayo moodooyinka xayawaanka ee adag ee FA iyo SCAs. Tashiyo badan, hababka aamusinta hiddaha ayaa la isticmaalaa, halka FA, tani ay ku lug leedahay xeelado kordhinta hiddaha.

Daaweynta hidde-sidaha ee la xiriirta ataxias-ka ayaa laga wada hadlay, oo ay ku jiraan:

1. Oligonucleotides-ka ka hortagga dareenka (ASOs), halkaas oo DNA-da ama RNA-da isku-darka ah ay la midoobaan mRNA ama micro RNA oo ay ka hortagaan soo saarista borotiinka sunta ah, waxayna u baahan yihiin maamul soo noqnoqda; 2. Vectors-ka la xiriira Adenovirus (AAVs), halkaas oo AAV-yadu ay hiddo-sideyaal daaweyn ah u gudbiyaan unug, kaas oo ah mid joogto ah, oo u baahan hal maamul; 3. Faragelinta RNA (RNAi), halkaas oo taxanaha hidde-sideyaasha yaryar ay aamusiyaan hiddo-sideyaal gaar ah, iyagoo ka hortagaya inay soo saaraan borotiin waxyeello leh, una baahan maamul soo noqnoqda; 4. Tafatirka hidda-wadaha CRISPR, halkaas oo hidda-wadaha bartilmaameedka si toos ah wax looga beddelo, taas oo sidoo kale ah mid joogto ah.

Faa'iidooyinka iyo khasaarooyinka noocyadan daaweynta hidde-sidaha ee ataxias ayaa la barbar dhigay. Dhibaato ayaa ah in daawayntani ay u janjeerto inay u baahdaan maamul duullaan ah si daaweynta loo gaarsiiyo gobollada saxda ah ee maskaxda iyo habdhiska dhexe ee neerfaha, oo inta badan ku lug leh duritaanno goobo badan, oo ay ku jiraan duritaanno gudaha-parenchymal ah (maskaxda/cerebellum), irbado gudaha-cerebroventricular ah, cisternal, iyo lumbar ah, ama isku-darka kuwan, oo wata khataro ka imanaya hababkan.

Muxaadarada waxaa sidoo kale ku jiray kiisas guul leh oo daaweynta AAV ah oo ku dhaca dhallaanka qaba dheef-shiid kiimikaadka naadirka ah ee ataxias GM2 gangliosidosis (Eichler, 2025) iyo cudurka Canavan (Corti, 2023). Xaaladahan, dhallaanka waxay awoodeen inay noolaadaan waqti dheer oo ay la ildaran yihiin dhaqdhaqaaq yar, waxayna dhab ahaantii sameynayaan horumarro ku aaddan xaaladahan ba'an. Si kastaba ha ahaatee, waxaa jiray guul yar markii la isku dayay carruurta waaweyn, taas oo sidoo kale xaddiday waxyeellooyinka (tusaale ahaan, dystonia ee gangliosidosis-ka GM ee dhallinyarada). Tijaabo ASO ah oo ku saabsan cudurka Alexander (NCT04849741), oo leh natiijooyin dhiirigelin leh oo ku saabsan heerka sare, ayaa la sheegay. Tijaabooyinka caafimaad ee daaweynta hidde-sidaha ee hadda jira ayaa sidoo kale laga wada hadlay. Waxaa jira tijaabooyin ASO ah oo hadda lagu sameeyay spinocerebellar ataxias, inkastoo ay jirtay walaac ka dib markii tijaabada tominersen ASO ee cudurka Huntington ay keentay calaamado sii xumaanaya, taasoo keentay in tijaabo SCA3 la joojiyo 2023. Intaa waxaa dheer, tijaabooyinka AAV ee FA ayaa laga wada hadlay, oo ay ku jiraan dhiirigelinta xogta sare ee tijaabada loogu talagalay FA cardiomyopathy (NCT05445323), taas oo muujisay muujinta frataxin wadnaha oo wanaagsan iyo tusmada cufnaanta ventricular bidix.

Ugu dambeyntii, rajada laga qabo daawada shaqsiga ah, oo leh tijaabooyin N ee 1, ayaa sii kordheysa (Dies, 2026). Si kastaba ha ahaatee, waa inaan ka warqabnaa inaan ku jirno marxaladaha hore ee isticmaalka teknoolojiyadan beddeli kara, kuwaas oo wali wata khatar badan; laakiin tani way fiicnaan doontaa waqti ka dib, ugu dambeyntiina waxay keeni doontaa daaweyn ama daaweyn aad waxtar u leh. Laakiin waxaa jiri doona tijaabooyin iyo caqabado badan oo laga gudbi karo ka hor inta aynaan halkaas gaarin.

Kalfadhiga ayaa ku soo gabagabeeyay dood xiiso leh oo lala yeeshay dhagaystayaasha, taasoo ka tarjumaysa xiisaha sii kordhaya iyo filashooyinka ku xeeran daaweynta ataxia. Ka qaybgalayaashu waxay soo jeediyeen dhowr su'aalood oo feker leh oo ku saabsan isticmaalka hadda jira ee daaweynta soo ifbaxaysa, horumarinta hababka ku salaysan hidde-sidaha, iyo caqabadaha ku jira in horumarkan loo beddelo dhaqan caafimaad. Fiiro gaar ah ayaa la siiyay caqabadaha ka jira Latin Ameerika, oo ay ku jiraan helitaanka xaddidan ee baaritaanka hidde-sidaha, dib u dhaca ogaanshaha, kala duwanaanshaha sharciyeynta, iyo helitaanka aan sinnayn ee daaweynta cusub ee la ansixiyay. Doodahani waxay iftiimiyeen muhiimadda iskaashiga caalamiga ah, wadaagga aqoonta, iyo dhisidda awoodda gobolka si loo hubiyo in horumarka daaweynta ataxia si siman loogu hirgelin karo goobaha daryeelka caafimaadka ee kala duwan.

Isweydaarsiga firfircoon ayaa hoosta ka xariiqay xiisaha iyo taxaddarka lagu garto xilligan xaadirka ah ee cilmi-baarista ataxia, iyadoo goobtu ay sii waddo inay u gudubto daaweyn waxtar leh oo la heli karo.

 

tixraacyada

Ariello L, Rastall D, Rosenthal L. Daaweynta ataxias-ka maskaxda ee neerfaha ee dadka waaweyn ee bilowga ah. Daaweynta neerfaha. 2025 Diseembar 11:e00805

Corti M, Byrne B, Gessler D, iwm. Daaweynta hidda-wadaha ee fayraska dhexdhexaadiya ee la xiriirta Adeno ee bukaanka qaba cudurka Canavan iyadoo la adeegsanayo laba dariiq oo maamul iyo habaynta difaaca jirka. Mol Ther Methods Clin Dev. 2023 Juun 19:30:303-314.

Dies K, Yu T, Chamberlin N, iwm. Doorka Xarumaha Caafimaadka Tacliinta ee Horumarinta Daaweynta Tijaabada Shakhsi ahaaneed: Tixgelinnada Muhiimka ah. Neerfayaasha. 2026 Febraayo 10;106(3):e214610

Eichler F, Cataltepe O, Daci R, iwm. Daaweynta hidda-wadaha rAAVrh8 ee laba-geesoodka ah ee loogu talagalay gangliosidosis-ka GM2: tijaabo wejiga 1/2 ah. Nat Med. Sebteembar 2025;31(9):2927-2935.

Indelicato E, Delatycki M, Farmer J, iwm. Aragti caalami ah oo ku saabsan horumarka cilmi-baarista iyo caqabadaha mustaqbalka ee Friedreich ataxia. Nat Rev Neurol. 2025 Abriil;21(4):204-215.

Lynch D, Chin M, Delatycki M, iwm. Badbaadada iyo Waxtarka Omaveloxolone ee Friedreich Ataxia (Daraasadda MOXIe). Ann Neurol. 2021 Febraayo;89(2):212-225.

Lynch D, Goldsberry A, Rummey C, iwm. Isbarbardhigga u janjeera ee daaweynta omaveloxolone iyo xogta taariikhda dabiiciga ah ee Friedreich's ataxia. Ann Clin Transl Neurol. 2024 Jan;11(1):4-16.

Sartorelli J, Ng J, Rahim A, iwm. Daaweynta hidde-sidaha ee loogu talagalay khalkhalka dhaqdhaqaaqa - xaaladda hadda jirta. J Neurol. 22 Febraayo 2025;272(3):220.

Vázquez-Mojena Y, León-Arcia K, González-Zaldivar Y, iyo al. Daaweynta hidda-wadaha ee Polyglutamine Spinocerebellar Ataxias: Horumarrada, Caqabadaha, iyo Aragtiyooyinka. Dhaqdhaqaaqa Dhaqdhaqaaqa 2021 Dec;36 (12):2731-2744.